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Loss of Function of the Nuclear Receptor NR2F2,
Encoding COUP-TF2, Causes Testis Development
and Cardiac Defects in 46,XX Children
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Emerging evidence frommurine studies suggests that mammalian sex determination is the outcome of an imbalance between mutually
antagonistic male and female regulatory networks that canalize development down one pathway while actively repressing the other.
However, in contrast to testis formation, the gene regulatory pathways governing mammalian ovary development have remained
elusive. We performed exome or Sanger sequencing on 79 46,XX SRY-negative individuals with either unexplained virilization or
with testicular/ovotesticular disorders/differences of sex development (TDSD/OTDSD).We identified heterozygous frameshift mutations
in NR2F2, encoding COUP-TF2, in three children. One carried a c.103_109delGGCGCCC (p.Gly35Argfs*75) mutation, while two others
carried a c.97_103delCCGCCCG (p.Pro33Alafs*77) mutation. In two of three children the mutation was de novo. All three children pre-
sented with congenital heart disease (CHD), one child with congenital diaphragmatic hernia (CDH), and two children with blepharo-
phimosis-ptosis-epicanthus inversus syndrome (BPES). The three children had androgen production, virilization of external genitalia,
and biochemical or histological evidence of testicular tissue. We demonstrate a highly significant association between the NR2F2
loss-of-function mutations and this syndromic form of DSD (p ¼ 2.44 3 108). We show that COUP-TF2 is highly abundant in a
FOXL2-negative stromal cell population of the fetal human ovary. In contrast to the mouse, these data establish COUP-TF2 as a human
‘‘pro-ovary’’ and ‘‘anti-testis’’ sex-determining factor in female gonads. Furthermore, the data presented here provide additional evidence
of the emerging importance of nuclear receptors in establishing human ovarian identity and indicate that nuclear receptors may have
divergent functions in mouse and human biology.The sex chromosomes of an individual usually direct
gonadal sex development toward either a testis or ovary
pathway. In 46,XY individuals, the presence of the Y
chromosome testis-determining gene SRY (MIM: 601947)
triggers a genetic cascade that both initiates testis forma-
tion and represses the formation of the ovary.1 Although
many factors are known to be involved in early testis devel-
opment, far less is known about genetic factors controlling
the ovary.1 However, emerging evidence suggests that
ovary development involves more than just a default
(passive) pathway,2 consistent with the Z-factor theory
proposed 25 years ago that the XX gonad expresses an
elusive factor that actively promotes both ‘‘anti-testis’’
and ‘‘pro-ovary’’ functions.3
The genomic analysis of 46,XX individuals with testes
(sometimes known as testicular disorders/differences of
sex development [TDSD]; [MIM: 400045]) or ovotestes
(ovotesticular DSD [OTDSD]) supports the hypothesis
that ‘‘pro-testis/anti-ovary’’ or ‘‘pro-ovary/anti-testis’’ ge-
netic pathways exist.4–6 These children typically present
with virilized genitalia due to testosterone production
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tion of the testis-determining SRY gene, usually onto one
of the X chromosomes, whereas a small proportion have
chromosomal rearrangements associated with upregula-
tion (gain-of-function) of SOX gene expression (e.g., dupli-
cations of the RevSex [MIM: 616425] enhancer of SOX9
[MIM: 608160] and rearrangements of the SOX3 locus
[MIM: 800833]).5,6 This ectopic SOX gene expression in-
creases ‘‘pro-testis’’ factors in the early developing ovary
and results in a reprogramming of cellular sex identity to
testis-typical Sertoli cells. Other rare forms of 46,XX DSD
can occur due to mutations (loss-of-function) involving
genes that are ‘‘pro-ovary/anti-testis.’’ The best example
of this is in the WNT4/RSPO1 signaling pathway, which
stabilizes b-catenin and is required for ovary develop-
ment.7 Very rare heterozygous or homozygous mutations
inWNT4 (MIM: 603490) cause Mu¨llerian aplasia/hyperan-
drogenism (MIM: 158330)8 or testis development (SERKAL
syndrome [MIM: 611812]) in 46,XX individuals, respec-
tively, whereas homozygous RSPO1 (MIM: 609595) muta-
tions are also associated with testis formation and skin
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(MIM: 605597) is a forkhead/winged helix transcription
factor, which is also a potential ‘‘pro-ovary’’ and ‘‘anti-
testis’’ gene. Goat XX fetuses lacking Foxl2 have gonads
resembling testes and the induced absence of Foxl2 in adult
XX mice results in trans-differentiation of the ovaries
into a testis-like gonad.9–11 In humans, heterozygous
loss-of-function FOXL2 mutations are associated with
autosomal-dominant blepharophimosis-ptosis-epicanthus
inversus syndrome (BPES [MIM: 110100]) either with
(type I) or without (type 2) ovarian insufficiency as well
as ovarian insufficiency without BPES (MIM: 608996),
but homozygous FOXL2 disruption has not been
described.10 The limited understanding of the genes
involved in ovary formation means that for most children
with OTDSD/TDSD, the molecular basis is currently
unknown.
Here, we report the molecular etiology of a syndromic
form of 46,XX DSD that includes genital virilization,
congenital heart disease (CHD), and variable somatic
anomalies including BPES and congenital diaphragmatic
hernia (CDH). This syndrome is caused by protein-trun-
cating mutations in the orphan nuclear receptor NR2F2
(MIM: 107773). NR2F2 encodes the transcription factor
chicken ovalbumin upstream promoter transcription
factor 2 (COUP-TF2).12 Our data indicate that in the early
developing human chromosomal female XX gonad,
COUP-TF2 is a human ‘‘pro-ovary’’ and ‘‘anti-testis’’ sex-
determining factor.
Following written informed consent and with local
ethics committee approvals, whole-exome sequencing
was performed on 69 46,XX individuals with either unex-
plained virilization (n ¼ 14) or unexplained OTDSD/TDSD
(n ¼ 55) as described elsewhere.13 Sanger sequencing of
NR2F2 was performed on DNA from a further 10 individ-
uals with 46,XX OTDSD/TDSD where there was insuffi-
cient DNA for complete exome analysis. Exclusion criteria
included rearrangements involving SOX genes, mutations
in either WNT4 or RSPO1, proven or suspected congenital
adrenal hyperplasia (CAH), or the presence of SRY. All sam-
ples underwent array comparative genomic hybridization
to confirm normal ploidy. Of the 79 children studied, 74
had no additional syndromic features. Of the 5 children
with additional features, 3 were unrelated children with
OTDSD/TDSD and CHD (with or without BPES), one had
46,XX TDSD with cerebral leukodystrophy, and another
had 46,XX TDSD with multiple congenital anomalies,
learning difficulties, and alopecia.
Analysis of exome sequencing datasets identified two
individuals (individuals 1 and 2) with near-identical
heterozygous frameshift mutations in NR2F2 (GenBank:
NM_021005.3), c.103_109delGGCGCCC (p.Gly35Argfs*
75), and c.97_103delCCGCCCG (p.Pro33Alafs*77)
(Table 1). These mutations were not present in parental
DNA and hence are de novo. No other shared genes
carrying de novo mutations were identified in the data-
sets. The mutations are predicted to result in the genera-
tion of a downstream termination codon (Figures 1A488 The American Journal of Human Genetics 102, 487–493, Marchand 1F). Both children presented with suspected
OTDSD/TDSD (Table 1) and congenital heart disease
(CHD). Individual 1 had a left congenital diaphragmatic
hernia (CDH) and died shortly after birth due to hypo-
plasia of the left heart. Analysis of an additional 10
individuals with 46,XX OTDSD/TDSD, for whom there
was insufficient DNA for complete exome studies, re-
vealed a third unrelated child with OTDSD and CHD
harboring the c.97_103delCCGCCCG (p.Pro33Alafs*77)
mutation (Table 1, individual 3). Since the parents of
this child were unavailable for study, the mode of trans-
mission of the mutation is unknown. The diagnosis
of 46,XX OTDSD was confirmed by histology of the
gonad (Figure 1B). Individuals 2 and 3 also had BPES
(Figure 1C). In all three children, potentially pathogenic
mutations were not identified in any other genes known
to be involved in DSD and high-resolution array compar-
ative genomic hybridization (aCGH) did not indicate re-
arrangements involving DSD-associated genes. These
frameshift mutations are absent from the public variant
databases and they were detected only in the three indi-
viduals in the cohort who had cardiac anomalies
together with 46,XX DSD.
NR2F2 is one the most conserved genes in the human
genome and is intolerant to protein-truncating vari-
ants.14 To exclude the possibility that these NR2F2
mutations may be a chance finding, we performed Fisher’s
exact tests (two-tailed) on the frequency of protein-trun-
cating mutations found in the case subjects and compared
this to rare missense mutations from 6,489 control Euro-
pean American and African American cohorts in the
NHLBI-ESP project. A rare variant is defined as a variant
with an allelic frequency of <1% in publically available
databases. We found no protein-truncating mutations
present in the control populations. We found a highly sig-
nificant enrichment for the NR2F2 protein-truncating
mutations identified in the three 46,XX DSD-affected
case subjects compared to the absence of protein-trun-
cating mutations in the control cohort (Fisher’s exact
test, two-tailed p ¼ 1.1 3 106). Even if we consider the
five missense mutations present in the control popula-
tion, the finding of three frameshift mutations in
the 46,XX DSD cohort is still highly significant (p ¼
6 3 105). The genetic evidence in favor of causality is
more compelling when one considers that the protein-
truncating mutations were specifically identified only in
the three children presenting with CHD and 46,XX DSD
(p ¼ 2.44 3 108).
NR2F2 encodes a key nuclear receptor, COUP-TF2.12 All
three frameshift mutations are present in the N-terminal
region of the protein and result in a downstream prema-
ture termination codon. RNA containing these mutations
is predicted to be degraded by nonsense-mediated decay.
Even if a truncated protein is produced, it would have
severely impaired biological activity since the protein
would lack both the DNA- and ligand-binding domains
(Figure 1F). An in silico analysis of the NR2F2 exon 1 with1, 2018
Table 1. Phenotypes, Genotypes, and Investigation of Three Children with Frameshift Mutations in NR2F2
Variable Individual 1 Individual 2 Individual 3
Ancestry Latino Senegalese Hungarian
Karyotype 46,XX SRY-negative 46,XX SRY-negative 46,XX SRY-negative
Birth weight (kg) 2.6 2.05 N/A
Cardiac hypoplastic L heart at birth; severely
dilated R ventricle with moderate RVH
and mild to moderately depressed RV
systolic function
persistent ostium secundum and ASD VSD at birth; spontaneous closure
of VSD at 9 years of age
External genitalia male, hyperpigmented; phallus 3 cm
with no hypospadias; gonads not
palpable
‘‘ambiguous’’ with phallus-like clitoris,
pigmented scrotum; gonads not palpable
‘‘ambiguous’’ Prader IV, pigmented
scrotum, phallus-like clitoris;
R, palpable gonad in the inguinal canal
Internal genitalia uterus not identified by US uterus present R, ductus-like Wolffian structures;
L, uterus, ovary, and Fallopian tube;
vagina and short urogenital sinus
Gonads not observed by US not observed by US or MRI pelvic ultrasound: R testis, L ovary;
histology: R gonad, testis tubules,
and ovarian tissue with oocytes
Other somatic
anomalies
left congenital diaphragmatic hernia BPES mild learning disabilities, minor limb
anomalies, hypertelorism, BPES
Endocrine data
(reference values)
Day 1: T, 135 ng/dL (20–64); 17-OHP,
120 ng/dL (11–170); LH, 5.1 IU/L
(0.02–7.0); FSH, 1.1 IU/L (0.16–4.1)
Day 11: T, 579 ng/dL (<130); AMH, 44 ng/mL
(<4.2); Inhibin B, 263 pg/mL (<110); FSH,
13.2 IU/L (<10); LH, 9.3 IU/L (0.9–3);
17-OHP, 127 ng/dL (<270)
Day 15: T, 327 ng/dL (<40);
AMH, 43.1 ng/mL (<4.2); Inhibin B,
217 pg/mL (<110); FSH, 6.9 IU/L (<10); LH,
5.1 IU/L (0.9–3); estradiol <5 pg/mL
1 month: T, 304 ng/dL (<40); AMH,
43.1 ng/mL (<4.2); Inhibin B, 230 pg/mL
(<110); FSH, 9 IU/L (<10); LH, 15.5 IU/L
(0.9–3); estradiol, <5 pg/mL
Day 17: T, 250 ng/dL (<40);
17-OHP, 185 ng/dL (40–490)
Day 30: T, 460 ng/dL (<40)
Day 45: T, 50 ng/dL (<40)
Day 73: T, 110 ng/dL (<40)
Mutation de novo, c.103_109delGGCGCCC
(p.Gly35Argfs*75)
de novo, c.97_103delCCGCCCG
(p.Pro33Alafs*77)
N/A, c.97_103delCCGCCCG
(p.Pro33Alafs*77)
Normal range refers to the range of basal levels in control subjects matched according to age and chromosomal sex with the case subjects. Conversion factors:
testosterone ng/dL x 0.034 for nmol/L; 17-OHP ng/dL x 0.0303 for nmol/L; AMH ng/mL x 7.14 for pmol/L; estradiol pg/mL x 3.67 for pmol/L.
Abbreviations: L, left; R, right; RVH, right ventricular hypertrophy; US, ultrasound; T, testosterone; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone;
FSH, follicle-stimulating hormone; ASD, atrial septal defect; MRI, magnetic resonance imaging; BPES, blepharophimosis ptosis epicanthus inversus syndrome;
AMH, anti-Mu¨llerian hormone; VSD, ventricular septal defect; N/A, not available. Individual 1 had a male-typical phenotype and high testosterone consistent
with testicular tissue; individual 2 had high AMH and inhibin B and high testosterone consistent with testicular tissue; individual 3 had high testosterone and
histological evidence of testicular tissue. In all situations, biochemical and genetic testing for other causes of virilization such as congenital adrenal hyperplasia
(e.g., 17-OHP) were negative.either of the two deletions using the tools Human Splicing
Factor 3 (HSF3), Splice Predictor, and RegRNA indicated
that neither the two deletions are predicted to generate
cryptic splice sites.
Murine Coup-tf2 protein has been reported to accu-
mulate during early ovary development in a distinct
Foxl2-negative somatic cell precursor.15 Although data
are limited, these cells with Coup-tf2 have been
hypothesized to be either mesenchymal cells and/or to
differentiate into theca cells.15 We therefore investigated
the profile of protein localization of COUP-TF2 in the
early developing human ovary. Human fetal ovaries
were isolated from material available following elective
termination of pregnancy during the first trimester at
the Department of Gynaecology at Copenhagen Univer-
sity Hospital (Rigshospitalet) and Hvidovre Hospital,
Denmark. The regional ethics committee approved this
study (permit number H-1-2012-007) and women gaveThe Ameritheir informed written and oral consent. We observed
widespread presence of COUP-TF2 in the stromal cell
population of the ovary at gestational weeks (GW) 9þ1
(Figures 2A–2C) and GW 9þ5 (Figures 2D and 2E),
whereas FOXL2 is limited to somatic cells of the
fetal ovary (Figure 2). At these stages, co-immunofluores-
cence demonstrated that FOXL2 and COUP-TF2 ap-
peared to be mutually exclusive at the cellular level
(Figure 2). Furthermore, analysis of RNA expression in
different tissues from adults reveals that NR2F2 is most
highly expressed in the ovary and female reproductive
tissues.16
We provide compelling genetic evidence for a role of
COUP-TF2 in early human ovary development. We iden-
tified three protein-truncating, complete loss-of-function
mutations that are acting in a dominant fashion.
These findings indicate that NR2F2 may function in a
dosage-sensitive manner, which is similar to other genecan Journal of Human Genetics 102, 487–493, March 1, 2018 489
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Figure 1. Identification of Three Individ-
uals with 46,XX DSD and Heterozygous
Frameshift Mutations in NR2F2
(A) Representative Sanger sequence chro-
matograms of individuals 1–3 showing
the positions of the frameshift mutations.
(B) Histology of the right gonad of individ-
ual 3 showing testicular tubule-like struc-
tures surrounded by stromal-like tissue
(scale bar corresponds to 100 mm).
(C) Blepharophimosis-ptosis-epicanthus in-
versus syndrome (BPES) of individual 3.
(D) Uterus (arrow) of individual 2 observed
by MRI.
(E) Pelvic radiography of individual 3
showing the vagina (V) and a short uro-
genital sinus (UrS).
(F) Schematic representation of COUP-TF2
showing the main functional domains
and the position and downstream conse-
quences of the three frameshift mutations.
The first zinc finger motif is highlighted in
green in the sequence alignment. The tran-
script ID is GenBank: NM_021005.3.mutations known to disrupt human sex determination.
This indicates that COUP-TF2 may be required to estab-
lish ovary identity during early human gonad develop-
ment by the repression of genes involved in testis
determination.
In mice, Coup-Tf2 is involved in the development of
multiple organs and tissues by modulating the expression
of downstream targets to promote cellular differenti-
ation, proliferation, migration, survival, and intercellular
communication.12,17–20 Globally, Coup-tf2 is highly abun-
dant at E14-E15 in the mesenchymal compartment of the
developing organs and declines after the completion of
organogenesis.12 The absence of Coup-tf2 in terminally
differentiated epithelium suggests that Coup-tf2 plays a
major role in the mesenchymal-epithelial transition.
Mice lacking Coup-tf2 die around E10 due to defects of
angiogenesis and heart development.20 Recently, ten hu-
man heterozygous missense, in-frame duplication, or
splice donor mutations in NR2F2 were reported in associa-
tion with cardiac defects (CHD [MIM: 615779]).21,22 Of
these mutations, four were confirmed as de novo. Most chil-
dren with NR2F2mutations had atrioventricular septal de-
fects, including a child with a hypoplastic left heart, which
is consistent with the cardiac phenotypes of the children
in this study. However, non-cardiac defects, such as virili-
zation or BPES, were not described in these cohorts. In
our study, individual 1 also presented with a left-sided dia-
phragmatic hernia (CDH). The p.Pro33Alafs*77 variant
was reported in a child with ASD, exotropia, and left-sided
CDH, suggesting that CDH is part of the phenotypic spec-
trum associated with NR2F2 mutations.23490 The American Journal of Human Genetics 102, 487–493, March 1, 2018The BPES phenotype observed in
children with NR2F2 mutations is
strikingly similar to that associated
with dominant mutations in FOXL2.These pathogenic variants cause BPES frequently together
with 46,XX premature ovarian insufficiency but testis
development has not been reported. BPES is thought to
originate following developmental defects in peri-ocular
mesenchymal cells, which are required to form the levator
smoothmuscle, tarsus, andMeibomian glands. Coup-tf2 is
known to play crucial roles in the formation of the
morphology of the murine eye, and given the similarities
in the phenotypes, it would be of interest to determine
whether FOXL2 and COUP-TF2 are acting in the same
developmental pathway.24
In contrast to cardiac development, the role(s) of
COUP-TF2 in early gonad development has yet to be fully
defined. In the developing fetal rat testis, partial inhibition
of Coup-tf2 by phthalates causes expansion of Leydig cells
and an increase in the intratesticular testosterone con-
centration, consistent with Coup-tf2 being a factor repres-
sing fetal androgenization.19 The protein localization of
COUP-TF2 in human fetal Leydig cells during the first
and second trimester could also be consistent with a
similar role of COUP-TF2 in repression of androgen pro-
duction.19,25 Indeed, there is a large body of evidence
from early studies to indicate that COUP-TF2 functions
as a transcriptional repressor of pro-testis genes.26
Data are also emerging for the role of Coup-Tf2 in female
reproductive development in mice but there seem to be
clear differences with humans. Murine Coup-Tf2þ/ XX
females show a wide range of reproductive anomalies
including reduced fecundity, irregular estrus cycles, de-
layed puberty, retarded postnatal growth, and reduced
levels of steroidogenic enzymes, but virilization and testis
A B 
C 
D E 
F 
Figure 2. Protein Localization of COUP-
TF2 and FOXL2 during Early Human
Ovarian Development
(A–C) Immunofluorescence showing pro-
tein localization of COUP-TF2 (green) and
FOXL2 (red) at gestational week (GW) 9þ1.
(D–F) Immunohistochemistry at GW 9þ5.
Extensive staining of COUP-FT2 is observed
in the stromal cell population of the devel-
oping fetal ovary. At both stages there ap-
pears to be a mutually exclusive presence
of FOXL2 and NR2F2, suggesting they
mark different somatic cell populations.
Dashed box in (A) and (C) indicates the
position of the expanded views. Nuclei
are counterstained with DAPI. Fetal age
was determined by scanning crown-rump
length and by evaluation of foot length.34
Sex of fetal samples was determined
by PCR for SRY as previously reported.35
Immunofluorescence was performed as
previously described.36 Primary antibodies
used were COUP-TFII/NR2F2 (Perseus Pro-
teomics, PP-H7147-60, diluted 1:100) and
FOXL2 (a kind gift from Dagmar Wilhelm,
diluted 1:100). Negative controls were
included and processed with the primary
antibody replaced by the dilution buffer
alone. None of the negative control slides
showed staining. Fluorescent images were
captured using an Olympus BX61 micro-
scope (Olympus) with the Cell Sens
Dimension software v.1.16.development has not been reported.27 Recently, a tam-
oxifen-inducible Wt1CreERT2 mouse model that targets
Nr2f2 in Wt1þ mesenchymal cells was described, where
knockout XX mice had both Mu¨llerian and Wolffian ducts
in the mesonephros.28 The ovaries of the mice lacking
Nr2f2 did not produce androgens, but an androgen-inde-
pendent activation of the p-ERK pathway in the Wolffian
duct epithelium was observed, leading to its maintenance
in XX mice. In striking contrast to the mouse model, viri-
lization of the genitalia in the three children reported here
was associated with elevated levels of both testosterone
and AMH and in one child the presence of testicular tissue
was confirmed by gonad histology.
The mechanism responsible for testis development asso-
ciated with COUP-TF2 variants remains to be defined.
Consistent with the Z-theory of a double repressor model
of human sex determination, COUP-TF2 acts both posi-
tively and negatively to modulate the expression of genes
involved in sex determination in other cellular and organ
contexts. For example, in the human endometrium,
COUP-TF2 is a positive regulator of the pro-ovary WNT4
gene and in mice Coup-tf2 negatively regulates the expres-
sion of the pro-testis Sox9 gene in the osteogenic mesen-
chyme.29,30
In addition to revealing unforeseen mechanisms in sex
development, our study also highlights the importance
of nuclear receptors (NR) in human development and dis-
ease. Humans have 48 different NRs with a diverse range ofThe Amerifunctions and next-generation sequencing approaches are
starting to identify novel and sometimes unexpected phe-
notypes associated with specific NR variants.31 Recently,
we described recurrent missense mutations that specif-
ically target the Arg92 residue of another nuclear receptor,
NR5A1 and which are associated with both 46,XX OTDSD
and TDSD in multiple individuals.32 When this mutation
is introduced into the XXmouse, it does not result in testis
formation.33 The data presented here provide additional
evidence of the emerging importance of nuclear receptors
in establishing human ovarian identity and indicate that
nuclear receptors may have divergent functions in mouse
and human biology.Acknowledgments
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